Beacon Securities Reiterates “Buy” Rating for Resverlogix Corp. (RVX)

Resverlogix Corp. (TSE:RVX)‘s stock had its “buy” rating reaffirmed by equities researchers at Beacon Securities in a research note issued on Wednesday.

Shares of Resverlogix Corp. (TSE:RVX) remained flat at $C$1.31 during trading hours on Wednesday. The company had a trading volume of 16,655 shares, compared to its average volume of 40,049. Resverlogix Corp. has a 12-month low of C$1.23 and a 12-month high of C$2.41.

TRADEMARK VIOLATION WARNING: “Beacon Securities Reiterates “Buy” Rating for Resverlogix Corp. (RVX)” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at

About Resverlogix Corp.

Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer’s disease and orphan diseases.

Receive News & Ratings for Resverlogix Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix Corp. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply